Depression

Neuronetics’ Breakthrough: How NeuroStar Therapy Is Transforming Lives Amid Rising Suicide Rates

MALVERN, PA — In recognition of Suicide Prevention Month, Neuronetics, Inc. (NASDAQ: STIM) is spotlighting the impactful stories shared on its NeuroStar Voices Portal. This platform, launched last year, allows individuals …

Neuronetics’ Breakthrough: How NeuroStar Therapy Is Transforming Lives Amid Rising Suicide Rates Read More

NRx Pharmaceuticals

NRx Pharmaceuticals Clinches $5M Milestone Achievement for Breakthrough in Bipolar Depression Treatments

WILMINGTON, DE — NRx Pharmaceuticals, Inc. (NASDAQ: NRXP), a pivotal player within the healthcare industry, this week announced a significant milestone in their ongoing quest to combat suicidal bipolar depression. …

NRx Pharmaceuticals Clinches $5M Milestone Achievement for Breakthrough in Bipolar Depression Treatments Read More

NRx Pharmaceuticals

NRx Pharmaceuticals to Spotlight Ketamine’s Potential and Risks in Keynote Address at Sachs Neuroscience Innovation Forum

RADNOR, PA — NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) has announced that it will present a keynote address at the highly anticipated Sachs Neuroscience Innovation Forum in San Francisco later today.

NRx Pharmaceuticals to Spotlight Ketamine’s Potential and Risks in Keynote Address at Sachs Neuroscience Innovation Forum Read More

NRx Pharmaceuticals

NRx Pharmaceuticals and Nephron Pharmaceuticals Announce Joint Agreement to Develop Intravenous Ketamine to Treat Suicidal Depression

RADNOR, PA — NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) and Nephron Pharmaceuticals, Inc. announced the recent signing of a development and manufacturing agreement to manufacture a presentation of ketamine suitable for …

NRx Pharmaceuticals and Nephron Pharmaceuticals Announce Joint Agreement to Develop Intravenous Ketamine to Treat Suicidal Depression Read More